Advertisement
YOU ARE HERE: LAT HomeCollectionsExperiments

COLUMN ONE

DNA May Soon Be in Play

Gene therapy helps build muscle and offers hope in treating disease. The dangers are real, as is the temptation for athletes seeking an edge.

August 27, 2004|Alan Zarembo | Times Staff Writer

Dr. James Wilson never intended to create super-monkeys.

A pioneer in genetic engineering, he was experimenting with a way to insert single genes into muscle cells, a technique that could eventually be used to treat a variety of genetic illnesses.

He chose a gene that boosts levels of erythropoietin, or EPO, a key hormone in the production of oxygen-toting red blood cells and a convenient marker to measure his experiment's success.

But EPO has another claim to fame. Its synthetic version, created in the 1980s to treat anemia, is one of the most notorious performance-enhancing drugs in competitive sports, able to increase endurance by raising the oxygen supply to muscles.

In less than two weeks, many of Wilson's rhesus monkeys had red cell counts greater than those of world-class runners who train at high altitude.

By three weeks, they had a higher concentration of red cells than even the worst EPO abusers in sports.

And no drug was ever injected.

As the sports world vainly struggles against the epidemic of illegal drugs, science has already opened the door to the next frontier in fraud: "gene doping."

By introducing specific genes, the experimental technology has created bigger muscles, faster metabolism and greater endurance in laboratory animals. Hidden in cells, gene enhancements in humans would be much harder to detect than drugs.

"We know that gene therapy at some point will be abused," said Olivier Rabin, the director of science for the World Anti-Doping Agency in Montreal. "It will happen."

There is no evidence that any athlete has tried genetic alteration, but the agency added it last year to the international list of "banned methods" and had begun funding research to detect gene abuse.

The temptations for athletes are high. But they are not without risks.

For example, all eight monkeys in Wilson's experiment are dead.

*

Wilson, a boyish-looking professor of medicine at the University of Pennsylvania, knows the highs and lows of gene therapy, a field barely three decades old.

He led one of the earliest trials in humans -- to introduce genes to cure cystic fibrosis. In 1992, at 37, he became the first director of the university's Institute for Human Gene Therapy.

But seven years later, he found himself at the center of gene therapy's biggest disaster. Jesse Gelsinger, an 18-year-old from Tucson with a rare liver disorder, enrolled in one of Wilson's clinical trials. He received a genetic injection, which his body rejected. Four days later he was dead.

The university shut down the institute. The Food and Drug Administration, which ruled that Wilson should have stopped the experiment sooner, has moved to bar him from leading human trials.

Despite the setback, Wilson and other scientists are pushing ahead. There have been nearly 1,000 gene therapy clinical trials worldwide.

The field remains one of medicine's best hopes in the fight against disorders caused by defects in genes, such as diabetes and Parkinson's disease.

The concept of gene therapy first appeared in the late 1960s. As scientists learned how to manipulate DNA, they came to believe that genetic defects could be fixed by installing new genes.

To accomplish that, they had to figure out how to deliver the therapeutic genes to cells. The leading method today uses viruses, which naturally invade cells. Researchers snip out the harmful parts of the virus and splice in the new gene.

These "viral vectors" are typically injected into the body. In some cases, they are designed to permanently merge the new gene into the subject's DNA so that it is replicated and passed on when cells divide. In other cases, the virus deposits the new gene as a self-contained ring of DNA in the cell nucleus, where it remains for the life of the cell.

The problem is that the interactions among genes are still poorly understood and the therapeutic genes do not always land where scientists intend.

In humans, success has been limited and sobering. The most-cited example is the treatment of a fatal immune disorder known as X-linked SCID -- or "bubble boy disease" -- in 10 children in France. Eight recovered. Two developed leukemia after the new gene landed in a dangerous spot.

The stakes in gene therapy are unusually high. "You can't turn it off," Wilson said. "That's the problem."

It could be years or decades before viable therapies are on the market. Most clinical trials are conducted on terminally ill patients seeking a last resort.

Despite the risks, it didn't take long for sports officials to recognize the potential for athletes to abuse genetic technology.

"We know that some athletes are willing to take very high risks to enhance their performance," said Rabin, the antidoping official.

How much is an extra tenth of a second worth?

*

The week that H. Lee Sweeney, a physiologist at the University of Pennsylvania, announced that he had genetically engineering a group of freakishly muscular mice, he received a call from a high school football coach.

Advertisement
Los Angeles Times Articles
|
|
|